| Identification | Back Directory | [Name]
Baloxavir | [CAS]
1985605-59-1 | [Synonyms]
CPD2051
S-033447
Baloxavir
New Baloxavir
Baloxavir (Xofluza
Baloxavir USP/EP/BP
Baloxavir Impurity 10
BXA,endonuclease,S033447,Influenza Virus
influenza,RNA,inhibit,dolutegravir,Baloxavir,Inhibitor,cap-dependent,S 033447,CEN,transcription,replication
(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2’4]triazine-6,8- dione
(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03?]tetradeca-10,13-diene-9,12-dione
(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione
(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione
1H-[1,4]Oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, 12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,12,12a-tetrahydro-7-hydroxy-, (12aR)-
1H-[1,4]Oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione,12-[(11S)-7Chemicalbook,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-3,4,12,12a-tetrahydro-7-hydroxy-,(12aR)- | [EINECS(EC#)]
200-001-8 | [Molecular Formula]
C24H19F2N3O4S | [MDL Number]
MFCD31619273 | [MOL File]
1985605-59-1.mol | [Molecular Weight]
483.49 |
| Questions And Answer | Back Directory | [Uses]
Baloxavir is a drug employed in the treatment of influenza virus infection.
Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. |
| Chemical Properties | Back Directory | [Boiling point ]
644.7±65.0 °C(Predicted) | [density ]
1.63±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:41.67(Max Conc. mg/mL);86.19(Max Conc. mM) | [form ]
A solid | [pka]
4.50±1.00(Predicted) | [color ]
White to yellow | [InChIKey]
FIDLLEYNNRGVFR-CTNGQTDRSA-N | [SMILES]
N12C=CC(=O)C(O)=C1C(=O)N1CCOC[C@@]1([H])N2[C@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C21 | [CAS DataBase Reference]
1985605-59-1 |
| Hazard Information | Back Directory | [Description]
Baloxavir is a prodrug of baloxavir acid that selectively inhibits the cap-dependent endonuclease of the polymerase acidic subunit of the viral polymerase, offering clinical advantages such as a single-dose regimen and rapid viral clearance[1][2]. Baloxavir increases the model-based estimated viral clearance rate by 86% in patients with acute influenza and achieves a median viral clearance half-life of 5.7 hours[1]. Single-dose baloxavir provides an operational advantage owing to the long half-life of baloxavir acid, although its application carries the risk of selecting and spreading drug-resistant mutants[1]. | [Mechanism of action]
Baloxavir marboxil is an influenza therapeutic agent, specifically, an enzyme inhibitor targeting the influenza virus' cap-dependent endonuclease activity, one of the activities of the virus polymerase complex. In particular, it inhibits a process known as cap snatching, by which the virus derives short, capped primers from host cell RNA transcripts, which it then uses for polymerase-catalyzed synthesis of its needed viral mRNAs. A polymerase subunit binds to the host pre-mRNAs at their 5' caps, then the polymerase's endonuclease activity catalyzes its cleavage "after 10–13 nucleotides". As such, its mechanism is distinct from neuraminidase inhibitors such as oseltamivir and zanamivir. | [Side effects]
Common side effects following the single dose administration of baloxavir marboxil include diarrhea, bronchitis, common cold, headache, and nausea. Adverse events were reported in 21% of people who received baloxavir, 25% of those receiving placebo, and 25% of oseltamivir. | [storage]
Store at -20°C | [References]
[1] Jittamala, P., Schilling, W. H. K., Leopold, S. J., Watson, J. A., Kotchum, K., Wongnak, P., Seers, T., Asawasriworanan, T., Singh, S., Beer, E., Ngernseng, T., Suwannasin, K., Madmanee, W., Phommasone, K., Shrestha, S., de Aguiar, R. S., Batty, E. M., Teixeira, M. M., Karkey, A., … White, N. J. (2026). Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial. Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(26)00255-0
[2] Zhan, P., Ren, Y., Han, K., Jin, G., Yang, Y., Shi, L., & Ci, Y. (2026). Baloxavir Acid-Induced Mitochondrial Toxicity and Cell Cycle Arrest Contribute to Its Adverse Effects. International Journal of Molecular Sciences, 27 7. https://doi.org/10.3390/ijms27072967
|
|
| Company Name: |
BOYAN PHARMA Gold
|
| Telephone: |
18566078841 18566078841 |
| Website: |
boyanpharma.com/index.php?c=category&id=9 |
|